<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p22" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_22{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_22{left:341px;bottom:30px;}
#t3_22{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_22{left:377px;bottom:30px;}
#t5_22{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_22{left:540px;bottom:30px;}
#t7_22{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_22{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_22{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_22{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_22{left:285px;bottom:827px;letter-spacing:-0.25px;}
#tc_22{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_22{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_22{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_22{left:1086px;bottom:28px;letter-spacing:0.17px;}
#tg_22{left:36px;bottom:760px;letter-spacing:0.48px;}
#th_22{left:36px;bottom:741px;letter-spacing:0.25px;}
#ti_22{left:240px;bottom:760px;letter-spacing:0.32px;word-spacing:-0.31px;}
#tj_22{left:877px;bottom:760px;letter-spacing:0.28px;word-spacing:-0.12px;}
#tk_22{left:37px;bottom:533px;letter-spacing:-0.18px;}
#tl_22{left:37px;bottom:515px;letter-spacing:-0.11px;}
#tm_22{left:37px;bottom:497px;letter-spacing:-0.18px;}
#tn_22{left:37px;bottom:478px;letter-spacing:-0.19px;}
#to_22{left:246px;bottom:725px;letter-spacing:-0.1px;}
#tp_22{left:246px;bottom:707px;letter-spacing:-0.1px;}
#tq_22{left:334px;bottom:714px;letter-spacing:-0.13px;}
#tr_22{left:359px;bottom:707px;letter-spacing:-0.09px;}
#ts_22{left:246px;bottom:671px;letter-spacing:-0.1px;}
#tt_22{left:245px;bottom:604px;letter-spacing:-0.09px;}
#tu_22{left:245px;bottom:586px;letter-spacing:-0.09px;}
#tv_22{left:245px;bottom:567px;letter-spacing:-0.08px;}
#tw_22{left:245px;bottom:549px;letter-spacing:-0.08px;}
#tx_22{left:245px;bottom:531px;letter-spacing:-0.1px;}
#ty_22{left:328px;bottom:538px;letter-spacing:-0.1px;}
#tz_22{left:246px;bottom:454px;letter-spacing:-0.1px;}
#t10_22{left:246px;bottom:308px;letter-spacing:-0.08px;}
#t11_22{left:394px;bottom:627px;letter-spacing:-0.1px;}
#t12_22{left:644px;bottom:634px;letter-spacing:-0.48px;}
#t13_22{left:399px;bottom:512px;letter-spacing:-0.1px;}
#t14_22{left:625px;bottom:519px;letter-spacing:-0.48px;}
#t15_22{left:682px;bottom:602px;letter-spacing:-0.09px;}
#t16_22{left:682px;bottom:584px;letter-spacing:-0.09px;}
#t17_22{left:682px;bottom:565px;letter-spacing:-0.1px;}
#t18_22{left:682px;bottom:465px;letter-spacing:-0.08px;}
#t19_22{left:682px;bottom:446px;letter-spacing:-0.09px;}
#t1a_22{left:747px;bottom:454px;letter-spacing:-0.48px;}
#t1b_22{left:877px;bottom:593px;letter-spacing:-0.09px;}
#t1c_22{left:877px;bottom:575px;letter-spacing:-0.1px;}
#t1d_22{left:964px;bottom:583px;letter-spacing:-0.11px;}
#t1e_22{left:877px;bottom:486px;letter-spacing:-0.13px;}
#t1f_22{left:899px;bottom:493px;}
#t1g_22{left:877px;bottom:468px;letter-spacing:-0.1px;}
#t1h_22{left:877px;bottom:449px;letter-spacing:-0.1px;}
#t1i_22{left:877px;bottom:431px;letter-spacing:-0.1px;}
#t1j_22{left:964px;bottom:438px;letter-spacing:-0.12px;}
#t1k_22{left:1067px;bottom:620px;letter-spacing:-0.1px;}
#t1l_22{left:1067px;bottom:602px;letter-spacing:-0.09px;}
#t1m_22{left:1067px;bottom:584px;letter-spacing:-0.08px;}
#t1n_22{left:1067px;bottom:515px;letter-spacing:-0.09px;}
#t1o_22{left:1067px;bottom:497px;letter-spacing:-0.06px;}
#t1p_22{left:1067px;bottom:478px;letter-spacing:-0.08px;}
#t1q_22{left:1067px;bottom:460px;letter-spacing:-0.1px;}
#t1r_22{left:1067px;bottom:442px;letter-spacing:-0.25px;}
#t1s_22{left:877px;bottom:725px;letter-spacing:-0.09px;}
#t1t_22{left:877px;bottom:707px;letter-spacing:-0.09px;}
#t1u_22{left:943px;bottom:707px;letter-spacing:-0.25px;}
#t1v_22{left:931px;bottom:397px;letter-spacing:-0.09px;}
#t1w_22{left:931px;bottom:379px;letter-spacing:-0.09px;}
#t1x_22{left:998px;bottom:379px;letter-spacing:-0.25px;}
#t1y_22{left:36px;bottom:267px;}
#t1z_22{left:45px;bottom:261px;letter-spacing:0.13px;}
#t20_22{left:260px;bottom:261px;}
#t21_22{left:36px;bottom:252px;}
#t22_22{left:42px;bottom:246px;letter-spacing:0.11px;word-spacing:0.01px;}
#t23_22{left:45px;bottom:231px;letter-spacing:0.12px;}
#t24_22{left:45px;bottom:215px;letter-spacing:0.13px;}
#t25_22{left:36px;bottom:206px;}
#t26_22{left:46px;bottom:200px;letter-spacing:0.13px;word-spacing:-0.06px;}
#t27_22{left:332px;bottom:200px;}
#t28_22{left:36px;bottom:191px;}
#t29_22{left:46px;bottom:185px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t2a_22{left:45px;bottom:169px;letter-spacing:0.03px;}
#t2b_22{left:109px;bottom:169px;}
#t2c_22{left:36px;bottom:160px;}
#t2d_22{left:46px;bottom:154px;letter-spacing:0.12px;}
#t2e_22{left:78px;bottom:154px;letter-spacing:0.12px;}
#t2f_22{left:156px;bottom:154px;letter-spacing:0.08px;word-spacing:0.05px;}
#t2g_22{left:36px;bottom:145px;}
#t2h_22{left:43px;bottom:139px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2i_22{left:45px;bottom:124px;letter-spacing:0.11px;word-spacing:0.01px;}
#t2j_22{left:45px;bottom:108px;letter-spacing:0.12px;word-spacing:-0.11px;}
#t2k_22{left:404px;bottom:108px;letter-spacing:-0.13px;}
#t2l_22{left:436px;bottom:108px;letter-spacing:0.08px;}
#t2m_22{left:551px;bottom:269px;}
#t2n_22{left:561px;bottom:263px;letter-spacing:0.12px;}
#t2o_22{left:560px;bottom:247px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2p_22{left:560px;bottom:232px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2q_22{left:560px;bottom:217px;letter-spacing:0.13px;}
#t2r_22{left:644px;bottom:217px;letter-spacing:0.12px;word-spacing:-0.02px;}
#t2s_22{left:560px;bottom:201px;letter-spacing:0.12px;word-spacing:-0.02px;}
#t2t_22{left:560px;bottom:186px;letter-spacing:0.12px;}
#t2u_22{left:551px;bottom:177px;}
#t2v_22{left:558px;bottom:171px;letter-spacing:0.12px;}
#t2w_22{left:560px;bottom:156px;letter-spacing:0.12px;}
#t2x_22{left:560px;bottom:140px;letter-spacing:0.13px;}
#t2y_22{left:551px;bottom:131px;}
#t2z_22{left:561px;bottom:125px;letter-spacing:0.12px;}
#t30_22{left:560px;bottom:110px;letter-spacing:0.12px;word-spacing:0.01px;}
#t31_22{left:36px;bottom:778px;letter-spacing:-0.15px;word-spacing:0.06px;}
#t32_22{left:246px;bottom:341px;letter-spacing:-0.1px;}
#t33_22{left:246px;bottom:407px;letter-spacing:-0.1px;}
#t34_22{left:441px;bottom:414px;letter-spacing:-0.09px;}
#t35_22{left:246px;bottom:388px;letter-spacing:-0.09px;}
#t36_22{left:465px;bottom:396px;}
#t37_22{left:246px;bottom:370px;letter-spacing:-0.1px;}
#t38_22{left:432px;bottom:377px;letter-spacing:-0.12px;}
#t39_22{left:514px;bottom:726px;letter-spacing:-0.1px;}
#t3a_22{left:514px;bottom:706px;letter-spacing:-0.09px;}
#t3b_22{left:519px;bottom:398px;letter-spacing:-0.1px;}
#t3c_22{left:519px;bottom:378px;letter-spacing:-0.09px;}
#t3d_22{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_22{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_22{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_22{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_22{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_22{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_22{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_22{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s7_22{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s8_22{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s9_22{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sa_22{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sb_22{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sc_22{font-size:14px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_22{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts22" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg22Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg22" style="-webkit-user-select: none;"><object width="1210" height="935" data="22/22.svg" type="image/svg+xml" id="pdf22" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_22" class="t s0_22">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_22" class="t s1_22">® </span>
<span id="t3_22" class="t s0_22">(NCCN </span>
<span id="t4_22" class="t s1_22">® </span>
<span id="t5_22" class="t s0_22">), All rights reserved. NCCN Guidelines </span>
<span id="t6_22" class="t s1_22">® </span>
<span id="t7_22" class="t s0_22">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_22" class="t s2_22">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_22" class="t s2_22">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_22" class="t s3_22">NCCN Guidelines Version 4.2024 </span>
<span id="tb_22" class="t s3_22">Cancer of the Oropharynx (p16 [HPV]-positive) </span>
<span id="tc_22" class="t s4_22">NCCN Guidelines Index </span>
<span id="td_22" class="t s4_22">Table of Contents </span>
<span id="te_22" class="t s4_22">Discussion </span>
<span id="tf_22" class="t s5_22">ORPHPV-4 </span>
<span id="tg_22" class="t s5_22">CLINICAL </span>
<span id="th_22" class="t s5_22">STAGING </span>
<span id="ti_22" class="t s5_22">TREATMENT OF PRIMARY AND NECK </span><span id="tj_22" class="t s5_22">ADJUVANT TREATMENT </span>
<span id="tk_22" class="t s5_22">p16 (HPV)-positive </span>
<span id="tl_22" class="t s5_22">T0–3,N3 </span>
<span id="tm_22" class="t s5_22">or </span>
<span id="tn_22" class="t s5_22">T4,N0–3 </span>
<span id="to_22" class="t s5_22">Concurrent systemic </span>
<span id="tp_22" class="t s5_22">therapy/RT </span>
<span id="tq_22" class="t s6_22">n,o </span>
<span id="tr_22" class="t s5_22">(preferred) </span>
<span id="ts_22" class="t s5_22">or </span>
<span id="tt_22" class="t s5_22">Resection of </span>
<span id="tu_22" class="t s5_22">primary and </span>
<span id="tv_22" class="t s5_22">ipsilateral or </span>
<span id="tw_22" class="t s5_22">bilateral neck </span>
<span id="tx_22" class="t s5_22">dissection </span>
<span id="ty_22" class="t s6_22">k,l,v </span>
<span id="tz_22" class="t s5_22">or </span>
<span id="t10_22" class="t s5_22">Clinical trials </span>
<span id="t11_22" class="t s5_22">No adverse pathologic features </span>
<span id="t12_22" class="t s6_22">r,s </span>
<span id="t13_22" class="t s5_22">Adverse pathologic features </span>
<span id="t14_22" class="t s6_22">r,s </span>
<span id="t15_22" class="t s5_22">Extranodal </span>
<span id="t16_22" class="t s5_22">extension and/or </span>
<span id="t17_22" class="t s5_22">positive margin </span>
<span id="t18_22" class="t s5_22">Other risk </span>
<span id="t19_22" class="t s5_22">features </span>
<span id="t1a_22" class="t s6_22">r,s </span>
<span id="t1b_22" class="t s5_22">Systemic </span>
<span id="t1c_22" class="t s5_22">therapy/RT </span>
<span id="t1d_22" class="t s6_22">n,o,t </span>
<span id="t1e_22" class="t s5_22">RT </span>
<span id="t1f_22" class="t s6_22">n </span>
<span id="t1g_22" class="t s5_22">or </span>
<span id="t1h_22" class="t s5_22">Consider systemic </span>
<span id="t1i_22" class="t s5_22">therapy/RT </span>
<span id="t1j_22" class="t s6_22">n,o </span>
<span id="t1k_22" class="t s5_22">Follow-up </span>
<span id="t1l_22" class="t s7_22">(FOLL-A, 1 </span>
<span id="t1m_22" class="t s7_22">of 2) </span>
<span id="t1n_22" class="t s5_22">Recurrent </span>
<span id="t1o_22" class="t s5_22">or </span>
<span id="t1p_22" class="t s5_22">persistent </span>
<span id="t1q_22" class="t s5_22">disease </span>
<span id="t1r_22" class="t s7_22">(ADV-3) </span>
<span id="t1s_22" class="t s5_22">Recurrent or persistent </span>
<span id="t1t_22" class="t s5_22">disease </span><span id="t1u_22" class="t s7_22">(ADV-3) </span>
<span id="t1v_22" class="t s5_22">Recurrent or persistent </span>
<span id="t1w_22" class="t s5_22">disease </span><span id="t1x_22" class="t s7_22">(ADV-3) </span>
<span id="t1y_22" class="t s8_22">k </span>
<span id="t1z_22" class="t s9_22">Principles of Surgery (SURG-A)</span><span id="t20_22" class="t sa_22">. </span>
<span id="t21_22" class="t s8_22">l </span>
<span id="t22_22" class="t sa_22">Tumors in the base of tongue, posterior pharyngeal wall, and soft palate </span>
<span id="t23_22" class="t sa_22">require consideration of bilateral neck treatment as do tumors of the tonsil </span>
<span id="t24_22" class="t sa_22">invading the tongue base. </span>
<span id="t25_22" class="t s8_22">n </span>
<span id="t26_22" class="t s9_22">Principles of Radiation Therapy (ORPH-A)</span><span id="t27_22" class="t sa_22">. </span>
<span id="t28_22" class="t s8_22">o </span>
<span id="t29_22" class="t s9_22">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="t2a_22" class="t s9_22">(SYST-A)</span><span id="t2b_22" class="t sa_22">. </span>
<span id="t2c_22" class="t s8_22">q </span>
<span id="t2d_22" class="t sa_22">See </span><span id="t2e_22" class="t s9_22">Discussion </span><span id="t2f_22" class="t sa_22">on induction chemotherapy. </span>
<span id="t2g_22" class="t s8_22">r </span>
<span id="t2h_22" class="t sa_22">Pathologic staging criteria differ from clinical staging criteria in HPV- </span>
<span id="t2i_22" class="t sa_22">mediated oropharyngeal cancer. For pathologic stage following resection, </span>
<span id="t2j_22" class="t sa_22">see AJCC 8th edition for appropriate staging criteria (</span><span id="t2k_22" class="t s9_22">ST-7</span><span id="t2l_22" class="t sa_22">). </span>
<span id="t2m_22" class="t s8_22">s </span>
<span id="t2n_22" class="t sa_22">Adverse pathologic features: extranodal extension, positive margins, close margins (&lt;3 </span>
<span id="t2o_22" class="t sa_22">mm), pT3 or pT4 primary, one positive node &gt;3 cm or multiple positive nodes, nodal </span>
<span id="t2p_22" class="t sa_22">disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion </span>
<span id="t2q_22" class="t s9_22">(Discussion)</span><span id="t2r_22" class="t sb_22">. The definition of an adverse pathologic feature in the context of HPV+ </span>
<span id="t2s_22" class="t sa_22">disease is an area of active research. This includes the presence and extent of extranodal </span>
<span id="t2t_22" class="t sa_22">extension, and the number of involved nodes. </span>
<span id="t2u_22" class="t s8_22">t </span>
<span id="t2v_22" class="t sb_22">The recommendations for patients at high risk with extranodal extension + positive margins </span>
<span id="t2w_22" class="t sb_22">are based on randomized studies involving patients for whom the HPV status of their </span>
<span id="t2x_22" class="t sa_22">tumors was not specified. </span>
<span id="t2y_22" class="t s8_22">v </span>
<span id="t2z_22" class="t sa_22">For those with clinical evidence of fixed or matted nodes or obvious extranodal extension, </span>
<span id="t30_22" class="t sa_22">resection is not recommended and concurrent systemic therapy/RT is preferred. </span>
<span id="t31_22" class="t s5_22">Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate </span>
<span id="t32_22" class="t s5_22">or </span>
<span id="t33_22" class="t s5_22">Induction chemotherapy </span>
<span id="t34_22" class="t sc_22">o,q </span>
<span id="t35_22" class="t s5_22">(category 3) followed by RT </span>
<span id="t36_22" class="t s6_22">n </span>
<span id="t37_22" class="t s5_22">or systemic therapy/RT </span>
<span id="t38_22" class="t s6_22">n,o </span>
<span id="t39_22" class="t s7_22">Post Systemic Therapy/RT or RT </span>
<span id="t3a_22" class="t s7_22">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t3b_22" class="t s7_22">Post Systemic Therapy/RT or RT </span>
<span id="t3c_22" class="t s7_22">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t3d_22" class="t sd_22">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
